[关键词]
[摘要]
目的 研究孟鲁司特钠片治疗慢性阻塞性肺疾病急性加重期的临床疗效。方法 收集新疆生产建设兵团第六师医院2013年6月-2015年12月收治的慢性阻塞性肺疾病急性加重期患者60例。所有随机分为对照组和治疗组,每组各30例。对照组进行抗感染、吸氧、化痰、支气管舒张剂等常规对症治疗。治疗组在对照组治疗基础上每晚口服孟鲁司特钠片,10 mg/次。两组患者均连续治疗4周。观察两组患者的临床疗效,同时比较两组治疗前后肺功能和炎症因子水平。结果 治疗后,对照组、治疗组的总有效率分别为73.33%、96.67%,两组总有效率比较差异有统计学意义(P<0.05)。治疗后,两组患者第1秒用力呼气容积占预计值百分比(FEV1% pred)、第1秒用力呼气量占用力肺活量比值(FEV1/FVC)、每分钟最大通气量占预计值百分比(MVV% pred)均显著改善,同组治疗前后比较差异有统计学意义(P<0.05);且治疗组的效果更佳,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者血清C反应蛋白(CRP)、降钙素原(PCT)水平均明显降低,同组治疗前后比较差异有统计学意义(P<0.05);且治疗组患者血清CRP、PCT水平下降更多,两组比较差异具有统计学意义(P<0.05)。结论 孟鲁司特钠治疗慢性阻塞性肺疾病急性加重期的效果显著,能有效改善肺功能,降低炎症因子水平,具有一定的临床推广应用价值。
[Key word]
[Abstract]
Objective To investigate the clinical effect of Montelukast Tablets in treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods Patients (60 cases) with AECOPD in Sixth Division Hospital, the Xinjiang Production and Construction Corps from June 2013 to December 2015 were randomly divided into control and treatment groups, and each group had 33 cases. Patients in the control group were treated with conventional treatment of anti infection, oxygen inhalation, expectorant and bronchodilator therapy. Patients in the treatment group were po administered with Montelukast Tablets on the basis of the control group before sleeping, 10 mg/time. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and pulmonary function and levels of inflammatory cytokines in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were73.33% and 96.67%, respectively, and there was difference between two groups (P<0.05). After treatment, FEV1%pred, FEV1/FVC, and MVV%pred in two groups were significantly improved, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of serum CRP and PCT in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Montelukast Tablets has clinical curative effect in treatment of AECOPD, can improve pulmonary function, and reduce levels of inflammatory cytokines, which has a certain clinical application value.
[中图分类号]
[基金项目]